ADM TRONICS UNLIMITED INC/DE Form 10QSB February 14, 2007

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 10-QSB

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2006

OR

[] TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to ____

COMMISSION FILE NO. 0-17629

ADM TRONICS UNLIMITED, INC. (Name of Small Business Issuer in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation or organization)

22-1896032 (I.R.S. Employer Identification Number)

224 Pegasus Ave., Northvale, New Jersey 07647 (Address of Principal Executive Offices)

Issuer's Telephone Number, including area code: (201) 767-6040

Check whether the Issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Issuer was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days:

YES [X] NO []

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

YES [] NO [X]

State the number of shares outstanding of each of the Issuer's classes of common equity, as of the latest practicable date:

53,882,037 shares of Common Stock, \$.0005 par value, as of February 7, 2007

1

INDEX

| | Page Number |
|---|-------------|
| Part I. Financial Information | |
| <pre>Item 1. Consolidated Financial Statements:</pre> | |
| Consolidated Balance Sheet - December 31, 2006 (unaudited) | 3 |
| Consolidated Statements of Operations - For the three months and nine months ended December 31, 2006 and 2005 (unaudited) | 4 |
| Statement of Stockholders' Equity For the nine months ended December 31, 2006 (unaudited) | 5 |
| Consolidated Statements of Cash Flows - For the nine months ended December 31, 2006 | |
| and 2005 (unaudited) | 6 |
| Notes to Consolidated Financial Statements (unaudited) | 7 |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | 10 |
| Item 3. Controls and Procedures | 13 |
| Part II. Other Information | |
| Item 1. Legal Proceedings | 14 |
| Item 6. Exhibits | 14 |

2

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET DECEMBER 31, 2006 (Unaudited)

ASSETS

| Current assets: Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of \$6,689 Inventories Prepaid expenses and other current assets | \$ 2,647,761 44,279 189,015 2,996 |
|---|---|
| Total current assets | 2,884,051 |
| Property and equipment, net of accumulated depreciation of \$55,495 | 17,012 |

| Inventory - long term portion Investment in Ivivi Due from Ivivi Loan receivable and accrued interest, officer Other assets | 122,838 3,011,241 8,604 92,565 92,317 |
|--|---|
| Total assets | \$ 6,228,628 ======= |
| LIABILITIES AND STOCKHOLDERS' EQUITY | |
| Current liabilities: Accounts payable Accrued expenses and other current liabilities | \$ 90,310 62,760 |
| Total current liabilities | 153,070 |
| Stockholders' equity: Preferred stock, \$.01 par value; 5,000,000 shares authorized, no shares issued and outstanding Common stock, \$.0005 par value; 150,000,000 shares authorized, 53,882,037 shares issued and outstanding Additional paid-in capital Accumulated deficit | 26,941 30,176,924 (24,128,307) |
| Total stockholders' equity | 6,075,558 |
| Total liabilities and stockholders' equity | \$ 6,228,628 ======= |

The accompanying notes are an integral part of these consolidated financial statements.

3

ADM TRONICS UNLIMITED, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2006 AND 2005

| | Three Months End | ded December 31, 2005 | Nine Months Er 2006 |
|-------------------------------------|------------------|--------------------------|------------------------|
| | (Unaudited) | (Unaudited) | (Unaudited) |
| Revenues | \$ 234,627 | \$ 470,671 | \$ 1,270,188 |
| Costs and expenses: | | | |
| Cost of sales | 79,794 | 238,559 | 330,845 |
| Research and development | 828 | 85 , 599 | 298,219 |
| Selling, general and administrative | 821,622 | 1,000,767 | 4,117,748 |

| Total operating expenses | 902,244 | 1,324,925 | 4,746,812 |
|---|---------------------------|------------------------|---------------------------|
| Operating loss | (667,617) | (854,254) | (3,476,624) |
| Interest and financing costs, net Change in fair value of warrant and | (1,263,146) | (430,310) | (3,128,569) |
| registration rights liabilities | (352,188) | 537,743 | (378,033) |
| Equity in net loss of Ivivi | (575 , 853) | | (575 , 853) |
| Net loss | \$ (2,858,804) ======= | \$ (746,821) ====== | \$ (7,559,079) ======= |
| Net loss per share, basic and diluted: | \$ (0.05) ====== | \$ (0.01) ====== | \$ (0.14) |
| Weighted average shares outstanding | 53,882,037 | 53,882,037 | 53,882,037 |

The accompanying notes are an integral part of these consolidated financial statements.

4

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
FOR THE NINE MONTHS ENDED DECEMBER 31, 2006
(Unaudited)

| | Common Stock | | Additional Paid-in | |
|--|---------------|--------|-----------------------|----|
| | Shares | Amount | Capital | |
| Balance, March 31, 2006 | 53,882,037 \$ | 26,941 | \$ 10,342,480 | \$ |
| Share based compensation | _ | - | 1,779,913 | |
| Reclassification of warrant liability upon effectiveness of Ivivi's registration statement | - | - | 630,312 | |
| Reclassification of unamortized loan costs and discount upon conversion of Ivivi debt | - | - | (669,347) | |
| Net assets of equity method Investment in Ivivi | | | 3,401,810 | |
| Increase in paid in capital of Ivivi | - | - | 184,284 | |
| Deconsolidation of Ivivi | | | 14,507,472 | |
| Net loss | _ | _ | - | |

5

ADM TRONICS UNLIMITED, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED DECEMBER 31, 2006 AND 2005 (Unaudited)

| | 2006 |
|---|--|
| CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash | \$(7,559,079) |
| used by operating activities: Depreciation and amortization Loss from equity investment Stock based compensation Amortization of loan costs and discount Share based financing penalties Provision for doubtful accounts Change in fair value of warrant and registration rights liabilities Amortization of deferred revenue Changes in operating assets and liabilities: (Increase) decrease in: Accounts receivable Inventory | 17,559 575,853 1,779,913 1,692,354 1,355,837 16,882 196,682 (4,833) (34,225) (30,330) |
| Prepaid expenses and other current assets Other assets Increase (decrease) in: Accounts payable and accrued expenses Deferred revenue | (101,785) (1,107) 1,268,414 290,000 |
| Net cash used by operating activities | (537 , 865) |
| CASH FLOWS FROM INVESTING ACTIVITIES: Cash retained by Ivivi Purchases of property and equipment | (67,483) (2,657) |
| Net cash used by investing activities | (70,140) |
| CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from notes payable, net Receivable from Ivivi Deferred offering costs | 245,725 2,598,662 (571,291) |
| Net cash provided by financing activities | 2,273,096 |

| nee increase (decrease) in each | 1,000,031 | ` |
|--|-------------------------|----------|
| Cash and cash equivalents, beginning of period | 982 , 670 | |
| Cash and cash equivalents, end of period | \$ 2,647,761 ======= | \$ == |
| Cash paid for: Interest Income taxes | \$ 166,174 | \$ |

The accompanying notes are an integral part of these consolidated financial statements.

6

ADM TRONICS UNLIMITED, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

Net increase (decrease) in cash

The accompanying condensed consolidated financial statements include the accounts of ADM Tronics Unlimited, Inc. and its subsidiaries ("we", "us", "the Company", "our", or "ADM"). These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the instructions to Form 10-QSB and do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation of the results for the interim periods have been included. Operating results for the three and nine months ended December 31, 2006 are not necessarily indicative of the results that may be expected for the full year ending March 31, 2007. The accompanying consolidated financial statements and the information included under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" should be read in conjunction with the Company's audited consolidated financial statements and related notes included in the Company's Form 10-KSB for the fiscal year ended March 31, 2006.

IVIVI OPERATIONS

ADM's former majority owned subsidiary, Ivivi Technologies, Inc. ("Ivivi"), filed a Registration Statement with the Securities and Exchange Commission ("SEC") for the initial public offering of a portion of its common stock. The Registration Statement was declared effective by the SEC on October 18, 2006. As a result of the consummation of Ivivi's initial public offering, we no longer own a majority of the outstanding common stock of Ivivi and do not control Ivivi's operations. We do own approximately 34% of Ivivi's outstanding common stock and can exert significant influence based upon the percentage of Ivivi's stock owned by us. As a result, our investment in Ivivi subsequent to October 18, 2006 is reported under the equity method of accounting, whereby we recognize our share of Ivivi's earnings or losses as they are incurred.

1.665.091

GOING CONCERN

In connection with the consummation of Ivivi's initial public offering during October 2006, (i) Ivivi repaid advances made to it by us aggregating approximately \$2.6 million and (ii) our outstanding convertible notes were converted into shares of Ivivi's common stock. While we continue to suffer operating and net losses and negative cash flows from operations, we believe that we can continue as a going concern for the next 12 months as a result of the inflow of cash from financing activities and the elimination of our long term debt.

USE OF ESTIMATES

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

LOSS PER SHARE

Basic and diluted loss per common share for all periods presented is computed based on the weighted average number of common shares outstanding during the periods presented as defined by SFAS No. 128, "Earnings Per Share". The assumed exercise of common stock equivalents was not utilized for the nine and three month periods ended December 31, 2006 and 2005 since the effect would be anti-dilutive. There were 11,626,854 common stock equivalents at December 31, 2006 and 50,109,612 at December 31, 2005.

STOCK OPTIONS AND WARRANTS

In April 2006, we adopted the fair value recognition provisions of SFAS No. 123(R), Accounting for Stock-Based Compensation, to account for compensation costs under our stock option plans and those of the our subsidiary. We previously utilized the intrinsic value method under Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (as amended) ("APB 25"). Pro forma information is computed using the Black-Sholes option pricing model at the date of grant of the options based on the following assumptions ranges: risk free interest rates of 3.62% to 4.6%; dividend yield of 0%; volatility factors of the expected market price of our common stock of 60% to 67%; and expected lives of the options of 2.5 to 5 years. The foregoing option valuation model requires input of highly subjective assumptions. Because common share purchase options granted to employees and directors have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value of estimates, the existing model does not in the opinion of the Company's management necessarily provide a reliable single measure of fair value of common share purchase options that we have granted to our employees and directors.

7

Pro forma information relating to employee and director common share purchase options is as follows:

For the Three Months Ended December 31, 2005 Net loss as reported \$ (746,821) Add: Shared based compensation expense included in reported net loss 2,856 Less: Share based compensation calculated under fair value method (5,261)Pro forma net loss \$ (749,226) -----\$ (0.01) Basic and diluted historical loss per share ======== \$ (0.01) Pro forma basic and diluted loss per share _____ NOTE 2 SEGMENT INFORMATION Information about segment information is as follows: CHEMICAL MEDICAL Nine Months Ended December 31, 2006: Revenues from external customers \$ 584,271 \$ 685,917 Segment loss (operating loss) (694,316) (2,782,308) Nine Months Ended December 31, 2005: 677,250 612,232 (70,285) (3,253,098) 677,250 Revenues from external customers Segment loss (operating loss) Three Months Ended December 31, 2006: Revenues from external customers 183,564 51,063 (225, 312) (442,305) Segment loss (operating loss) Three Months Ended December 31, 2005: Revenues from external customers 212,821 8,429 257,850 Segment loss (operating loss) (862,683) Total assets at December 31, 2006 6,181,480 47,148

NOTE 3 INVENTORY

Inventory at December 31, 2006 consists of the following:

NOTE 4 INVESTMENT IN IVIVI AND RELATED CAPITAL TRANSACTIONS

On October 18, 2006, Ivivi's Registration Statement on Form SB-2 was declared effective by the SEC. As a result, unsecured convertible notes in the aggregate principal amount of \$6,087,500, issued in our December 2004 and February 2005 joint private placement with Ivivi, automatically converted into shares of Ivivi common stock. Also upon effectiveness of the Registration Statement, unsecured convertible notes in the aggregate principal amount of \$2,000,000 issued in connection with Ivivi's November 2005 and March 2006 private placement to four institutional investors automatically converted into shares of Ivivi common stock.

Upon the conversion of the above debt into Ivivi common stock, unamortized loan costs and loan discount in the aggregate amount of \$669,347 were charged to additional paid-in capital. Unamortized discount in the amount of \$1,218,657 related to a beneficial conversion feature of the convertible debt was charged to interest expense upon conversion.

8

Upon the effectiveness of Ivivi's Registration Statement, certain ADM warrants which contained registration rights were cancelled. The fair value of these warrants was carried as a liability on our balance sheet. From October 1 through October 18, 2006, we recorded an expense for the change in fair value of these warrants in the amount of \$176,857. At October 18, 2006, the liability related to these warrants in the amount of \$630,312 was reclassified to additional paid-in capital. For the period from April 1 through October 18, 2006, we recorded an expense related to the change in fair value of these warrants in the amount of \$197,082.

Upon the consummation of Ivivi's initial public offering, we no longer own a majority of the outstanding common stock of Ivivi and do not control Ivivi's operations, but can exert significant influence based upon the percentage of Ivivi's stock owned by us. As a result, we have deconsolidated the operations of Ivivi subsequent to October 18, 2006. We have recorded a credit to additional paid-in capital in the amount of \$3,401,810 to record our proportionate investment in the net assets of Ivivi at October 18, 2006. Any future change of interest gains or losses related to our investment in Ivivi will be recorded as a credit or charge to additional paid-in capital.

During the period from October 18, 2006 to December 18, 2006, Ivivi recorded an increase in additional paid-in capital as a result of the recognition of compensation expense related to option grants to employees and others. We have recorded a proportional increase in our investment in Ivivi in the amount of \$184,284, with a related credit to additional paid-in capital.

In addition, Ivivi paid approximately \$2.6 million to us representing the balance in inter-company accounts at October 24, 2006 due to ADM from Ivivi for product manufacturing and allocations of personnel, professional services, rent, utilities, insurance and office support services provided by ADM to Ivivi for the period from March 1989 to October 2006.

The market value of our investment in Ivivi at December 31, 2006 was \$19,467,500. However, our common shares of Ivivi have not been registered with the SEC and are subject to restriction as a result of securities laws and a lock-up agreement for 12 months from Ivivi's IPO that has been executed by us.

The following table sets forth summarized results of operations of Ivivi for the period ended December 31, 2006:

April 1, 2006 October 19, 2006

| | to October 18, 2006 | | to December 31, 2006 | |
|-------------------------------|------------------------|----------------------|-------------------------|----------------------|
| Revenue Costs and expenses | \$ | 615,307 5,277,786 | \$ | 197,867 1,891,055 |
| Net loss | \$ | (4,662,479) | \$ | (1,693,188) |

NOTE 5 NON-CASH FINANCING AND INVESTING ACTIVITIES

As a result of Ivivi's Registration Statement on Form SB-2 being declared effective by the SEC, unsecured convertible notes in the aggregate principal amount of \$6,087,500, issued in our December 2004 and February 2005 joint private placement with Ivivi, automatically converted into shares of Ivivi common stock. Also upon effectiveness of the Registration Statement, unsecured convertible notes in the aggregate principal amount of \$2,000,000 issued in connection with Ivivi's November 2005 and March 2006 private placement to four institutional investors automatically converted into shares of Ivivi common stock.

Upon the conversion of the above debt into Ivivi common stock, unamortized loan costs and loan discount in the aggregate amount of \$669,347 were charged to additional paid-in capital.

Upon the effectiveness of Ivivi's Registration Statement, certain ADM warrants which contained registration rights were cancelled. At October 18, 2006, the liability related to these warrants in the amount of \$630,312 was reclassified to additional paid-in capital.

Upon the consummation of Ivivi's initial public offering, we no longer own a majority of the outstanding common stock of Ivivi and do not control Ivivi's operations but can exert significant influence based upon the percentage of Ivivi's stock owned by us. As a result, we have deconsolidated the operations of Ivivi subsequent to October 18, 2006. We have recorded a credit to additional paid—in capital in the amount of \$3,401,810 to record our proportionate investment in the net assets of Ivivi at October 18, 2006.

During the period from October 18, 2006 to December 18, 2006, Ivivi recorded an increase in additional paid-in capital as a result of the recognition of compensation expense related to option grants to employees and others. We have recorded a proportional increase in our investment in Ivivi in the amount of \$184,284, with a related credit to additional paid-in capital.

9

NOTE 6 CONCENTRATIONS

As of December 31, 2006, two customers represented 67% of our accounts receivable.

NOTE 7 RECENT ACCOUNTING PROUNCEMENTS

On July 13, 2006, FASB released its final interpretation on uncertain tax positions, FIN 48, "Account for Uncertainty in Income Taxes." FIN 48 addresses the recognition and measurement of uncertain income tax positions

using a "more-likely-than-not" threshold and introduces a number of new disclosure requirements. The guidance will become effective as of the beginning of a company's fiscal year beginning after December 15, 2006, for both public and non-public companies. We believe this new pronouncement will have an immaterial impact on our financial statements in future periods.

In September 2006, FASB issued Statement of Financial Accounting Standards No. 157 ("FAS 157"), Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles ("GAAP"), and expands disclosures about fair value measurements. FAS 157 applies under other accounting pronouncements that require or permit fair value measurements. Prior to FAS 157, there were different definitions of fair value and limited guidance for applying those definitions in GAAP. Moreover, that guidance was dispersed among the many accounting pronouncements that require fair value measurements. Differences in that guidance created inconsistencies that added to the complexity in applying GAAP. The changes to current practice resulting from the application of FAS 157 relate to the definition of fair value, the methods used to measure fair value, and the expanded disclosures about fair value measurements. FAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. We do not expect the adoption of FAS 157 to have an effect on our financial statements.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our operations and financial condition should be read in conjunction with the consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-QSB.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-QSB contains forward-looking statements within the meaning of the "safe harbor" provisions under section 21E of the Securities and Exchange Act of 1934 and the Private Securities Litigation Act of 1995. We use forward-looking statements in our description of our plans and objectives for future operations and assumptions underlying these plans and objectives. Forward-looking terminology includes the words "may", "expects", "believes", "anticipates", "intends", "forecasts", "projects", or similar terms, variations of such terms or the negative of such terms. These forward-looking statements are based on management's current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in such forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained in this report to reflect any change in our expectations or any changes in events, conditions or circumstances on which any forward-looking statement is based. Factors which could cause such results to differ materially from those described in the forward-looking statements include those set forth under "Item. 1 Description of Business - Risk Factors" and elsewhere in, or incorporated by reference into the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2006 and other filings with the Securities and Exchange Commission.

CRITICAL ACCOUNTING POLICIES

REVENUE RECOGNITION:

Sales revenues are recognized when products are shipped to end users and rental and lease revenues are recognized principally on either a monthly or a pay-per use basis in accordance with individual rental or lease agreements and are recognized on a monthly basis as earned. Shipments to distributors are recognized as sales where no right of return exists. This is generally the case with sales of chemicals. This is generally not the case with sales of the medical products. We recognize revenue from the sale of medical products when the products are shipped to end users. An increasing amount of rental revenue is recognized on a fixed monthly recurring basis as product is utilized by the end-user. Sales returns have been immaterial. Lease revenues through third party distributors have also been immaterial and there have been no sales through third party distributors. Our products are principally shipped on a "freight collect" basis. Shipping and handling charges are immaterial.

USE OF ESTIMATES:

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to reserves, deferred tax assets and valuation allowance, impairment of long-lived assets, fair value of equity instruments issued to consultants for services and fair value of equity instruments issued to others. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above- described items, are reasonable.

RECENT ACCOUNTING PROUNCEMENTS

On July 13, 2006, FASB released its final interpretation on uncertain tax positions, FIN 48, "Account for Uncertainty in Income Taxes." FIN 48 addresses the recognition and measurement of uncertain income tax positions using a "more-likely-than-not" threshold and introduces a number of new disclosure requirements. The guidance will become effective as of the beginning of a company's fiscal year beginning after December 15, 2006, for both public and non-public companies. We believe this new pronouncement will have an immaterial impact on our financial statements in future periods.

In September 2006, FASB issued

Statement of Financial Accounting Standards No. 157 ("FAS 157"), Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles ("GAAP"), and expands disclosures about fair value measurements. FAS 157 applies under other accounting pronouncements that require or permit fair value measurements. Prior to FAS 157, there were different definitions of fair value and limited guidance for applying those definitions in GAAP. Moreover, that guidance was dispersed among the many accounting pronouncements that require fair value measurements. Differences in that guidance created inconsistencies that added to the complexity in applying GAAP. The changes to current practice resulting from the application of FAS 157 relate to the definition of fair value, the methods used to measure fair value, and the expanded disclosures about fair value measurements. FAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. We do not expect the adoption of FAS 157 to have an effect on

our financial statements.

BUSINESS OVERVIEW

ADM is a corporation that was organized under the laws of the State of Delaware on November 24, 1969. During the three and nine months ended December 31, 2006 and 2005, our operations were conducted through ADM itself and its three subsidiaries, Ivivi Technologies, Inc. (through October 18, 2006), Pegasus Laboratories, Inc. and Sonotron Medical Systems, Inc. Ivivi has been deconsolidated as of October 18, 2006 upon the consummation of Ivivi's initial public offering, as we no longer own a majority of the outstanding common stock of Ivivi and do not control Ivivi's operations, but can exert significant influence based on the percentage of Ivivi's stock owned by us. As a result, our investment in Ivivi subsequent to October 18, 2006 is reported under the equity method of accounting.

10

We are a technology-based developer and manufacturer of diversified lines of products in the following three areas: (1) environmentally safe chemical products for industrial use, (2) therapeutic non-invasive electronic medical devices and (3) cosmetic and topical dermatological products. We have historically derived most of our revenues from the development, manufacture and sale of chemical products, and, to a lesser extent, from our therapeutic non-invasive electronic medical devices and topical dermatological products. However, during the nine months ended December 31, 2006, we derived an increased amount of our revenue from the sale and rental of our therapeutic non-invasive medical devices, through Ivivi. With the consummation of Ivivi's IPO, our continuing revenues will once again be derived primarily from the development, manufacture and sale of chemical products, and, to a lesser extent, from our therapeutic non- invasive electronic medical devices and topical dermatological products.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED DECEMBER 31, 2006 AS COMPARED TO DECEMBER 31, 2005

REVENUES

We have included the operations of our Ivivi subsidiary in our consolidated results of operations through October 18, 2006. For the three month periods ended December 31, 2006 and 2005, revenues from such operations were \$29,354 and \$224,073, respectively.

Revenues excluding Ivivi's operations were \$205,273 for the three months ended 2006 as compared to \$246,598 for the three months ended December 31, 2005, a decrease of \$41,325, or 17%. The decrease results from an overall reduction in sales volume as a result of the significant time commitment related to the completion of Ivivi's IPO and the successful negotiation and execution of Ivivi's agreement with Allergan , which took much of management's focus in the period. Gross profit was \$128,671 and \$115,769 for the three months ended December 31, 2006 and 2005, respectively, the reduction resulting from the decrease in sales volume.

NET LOSS

We have included the operations of our Ivivi subsidiary in our consolidated results of operations through October 18, 2006. For the three month periods ended December 31, 2006 and 2005, net loss attributable to the Ivivi operations was \$2,079,094 and \$757,655, respectively.

Net loss excluding Ivivi's operations for the three months ended December 31, 2006 was \$779,710 compared to net income for the three months ended December 31, 2005 of \$10,834. Selling, general and administrative expenses increased by \$247,793, or 228%, from \$108,226 to \$356,019, mainly due to a \$205,644 increase in consulting and professional fees. We also recorded an equity method investment loss of \$575,853 in 2006 from our investment in Ivivi. Interest income increased \$20,198, to \$23,490 in the three months ended December 31, 2006 from \$3,292 in the three months ended December 31, 2005, due to increased funds invested in a money market account.

RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED DECEMBER 31, 2006 AS COMPARED TO DECEMBER 31, 2005

REVENUES

We have included the operations of our Ivivi subsidiary in our consolidated results of operations through October 18, 2006. For the nine month periods ended December 31, 2006 and 2005, revenues from such operations were \$615,307 and \$540,661, respectively.

Revenues excluding Ivivi's operations were \$654,881 for the nine months ended December 31, 2006 as compared to \$748,821 for the nine months ended December 31, 2005, a decrease of \$93,940, or 12.5%. The decrease results from an overall reduction in sales volume as a result of the significant time commitment related to the completion of Ivivi's IPO and the successful negotiation and execution of Ivivi's agreement with Allergan , which took much of management's focus in the period. Gross profit was \$395,496 and \$402,479 for the three months ended December 31, 2006 and 2005, respectively, the reduction resulting from the decrease in sales volume.

11

NET LOSS

We have included the operations of our Ivivi subsidiary in our consolidated results of operations through October 18, 2006. For the nine month periods ended December 31, 2006 and 2005, net loss from the Ivivi operations was \$6,315,624 and \$3,171,459, respectively.

Net loss excluding Ivivi's operations for the nine months ended December 31, 2006 was \$1,243,455 compared to a net loss for the nine months ended December 31, 2005 of \$89,395. Selling, general and administrative expenses increased by \$590,835, or 118%, from \$500,244 to \$1,091,079, mainly due to a \$327,748 increase in consulting and professional fees and employee stock based compensation expense of \$276,201 in 2006, with no such expense in the comparable period. We also recorded an equity method investment loss of \$575,853 in 2006 from our investment in Ivivi. Interest income increased \$19,610, to \$27,981 in the nine months ended December 31, 2006 from \$8,371 in the nine months ended December 31, 2005, due to increased funds invested in a money market account.

LIQUIDITY AND CAPITAL RESOURCES

At December 31, 2006, we had cash and equivalents of \$2,647,761 as compared to \$982,670 at March 31, 2006. The increase was primarily the result of the payment

by Ivivi of approximately \$2.6 million representing the balance at October 24, 2006 due from Ivivi for product manufacturing and allocations of personnel, professional services, rent, utilities, insurance and office support services provided to Ivivi for the period from March 1989 to October 2006. These proceeds will be used for increased administrative and marketing costs in order to attempt to increase our revenue. Additionally, as a result of the consummation of Ivivi's initial public offering, we no longer have debt outstanding or any related warrant obligations. This debt, which amounted to approximately \$8.1 million, was converted automatically into shares of Ivivi's common stock on the initial public offering date. The market value of our investment in Ivivi at December 31, 2006 was \$19,467,500. However, our common shares of Ivivi have not been registered with the SEC and are subject to restriction as a result of securities laws and a lock-up agreement for 12 months from Ivivi's IPO that has been executed by us.

OPERATING ACTIVITIES

Net cash used by operating activities was \$537,865 for the nine months ended December 31, 2006 as compared to net cash used by operating activities of \$3,068,198 for the nine months ended December 31, 2005. The use of cash in 2006 was primarily due to a net loss of \$7,559,079, related mostly to Ivivi's operations, partially offset by non cash charges for the amortization of loan costs and amortization of discount of \$1,692,354 on the convertible notes issued in the private placements, stock based compensation of \$1,779,913, equity based penalty expense of \$1,355,837, equity investment loss of \$575,853 and increases in accounts payable and accrued expenses of \$1,268,414.

The use of cash in 2005 was primarily due to a net loss of \$3,260,854 related mostly to Ivivi's operations, partially offset by non cash charges for the amortization of loan costs and amortization of discount of \$519,216 on the convertible notes issued in the private placements, stock based compensation of \$140,962 and equity based penalty expense of \$238,018. We recorded a non-cash recovery of expense of \$1,264,177 due to the decrease in the fair value of the liability for warrants issued with registration rights in the 2005 period. In addition, we recorded an increase in accounts payable of \$453,020

INVESTING ACTIVITIES

For the nine months ended December 31, 2006, cash used in investing activities was \$70,140. Of this amount, \$2,657 was used for the purchase of office equipment and \$67,483 was retained by Ivivi after its IPO. For the nine months ended December 31, 2005, \$21,963 was used for the purchase of equipment.

FINANCING ACTIVITIES

During the nine months ended December 31, 2006, we paid \$571,291 for deferred costs related to the private placements as compared to \$245,300 during the nine months ended December 31, 2005. During the nine months ended December 31, 2006 and 2005, Ivivi had net proceeds from notes payable of \$245,725 and \$1,250,000, respectively. During 2006, we received repayments of advances made to Ivivi of \$2.598.662.

We do not have any material external sources of liquidity or unused sources of funds.

Our revenues, operations and cash flows over the past few years have declined. Management has recognized the situation and has developed a business plan to enhance the activities of its operations. Such plan includes retaining a sales representative and seeking to hire additional sales employees as well as seeking strategic relationships to help market and promote certain of our product lines. Although we expect that our available funds and funds generated from our operations, will be sufficient to meet our anticipated needs for a minimum of 12

months, we may need to obtain additional capital to continue to operate and grow our business. Our cash requirements may vary materially from those currently anticipated due to changes in our operations, including our marketing and sales activities, product development, and the timing of our receipt of revenues. We do not have any material external sources of liquidity or unused sources of funds. Our ability to obtain additional financing in the future will depend in part upon the prevailing capital market conditions, as well as our business performance. There can be no assurance that we will be successful in our efforts to arrange additional financing on terms satisfactory to us or at all.

12

ITEM 3. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d - 15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management necessarily applies its judgment in assessing the costs and benefits of such controls and procedures, which, by their nature, can provide only reasonable assurance regarding management's control objectives.

As of the end of the period covered by this Quarterly Report on Form 10-QSB, we carried out an evaluation, with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Securities Exchange Act Rule 13a-15. Based upon that evaluation as of December 31, 2006, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer, to ensure that such information is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms.

CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING.

The financial statements contained in our Quarterly Report on Form 10-QSB for our fiscal quarter ended September 30, 2005, required restatement related to the accounting for the fair value of warrants issued with convertible debt, and a beneficial conversion feature related to the convertible debt issued with respect to the private placements completed in December 2004 and February 2005 as previously accounted for by us.

We have taken the following steps in connection with its internal controls: (i) during the quarter ended June 30, 2005, we retained a certified public accountant as a consultant to assist with our financial reporting obligations and to improve our internal controls over financial reporting and (ii) during the quarter ended September 30, 2005, we hired a certified public accountant as a part-time employee responsible for assisting management with internal controls, financial reporting and closing our books and records.

However, there have been no changes in our internal controls over financial reporting that occurred during tour last fiscal quarter to which this Quarterly Report on Form 10- QSB relates that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

13

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None

ITEM 6. EXHIBITS.

- (a) Exhibit No.
- 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ADM TRONICS UNLIMITED, INC. (Registrant)

By: /s/ Andre' DiMino

Andre' DiMino, Chief Executive Officer and Chief Financial Officer

Dated: Northvale, New Jersey February 14, 2007